Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 October 2020 | Story Leonie Bolleurs | Photo Supplied
Disinfectants
Once they have an understanding of the development of disinfectant resistance, the Veterinary Biotechnology group will be able to make recommendations to hospitals and the agricultural industry on how to prevent the development of these resistant microorganisms.

SARS-CoV-2, an enveloped coronavirus, is susceptible to most disinfectants. Therefore, the majority of disinfectants, including those containing 70% ethanol, should be able to kill the virus fairly quickly.

Nevertheless, it was found that some bacteria are highly resistant to several commercially available disinfectants. These bacteria are currently still quite rare, and the work of the Veterinary Biotechnology group at the University of the Free State (UFS) aims to prevent the development of more highly resistant bacteria.

The research group in the Department of Microbial, Biochemical and Food Biotechnology is working on disinfectant resistance. They recently published an article, ‘Molecular basis of bacterial disinfectant resistance’.

Group members include: Prof Robert Bragg, professor in the department; Dr Charlotte Boucher, research associate; Samantha Mc Carlie, master’s student and laboratory manager; master’s students, Twyne Skein and Gunther Staats; honours students, Carlo Visser, Bernadette Belter, Boudine van der Walt, Jacky Huang, and Mart-Louise van Zyl; and an NRF intern, Gloria Kankam.

According to Mc Carlie, the work being done on disinfectant resistance is largely attributable to the major issues currently experienced with antibiotic resistance.

“Antibiotic resistance is becoming one of the biggest life-threatening challenges of our time – even overshadowing the current COVID-19 pandemic – as multidrug-resistant infections are becoming increasingly difficult to treat. Bacterial infections that are present in hospitals and agriculture are becoming unresponsive to many of the antibiotics currently in use, marking the start of a post-antibiotic era.”

It is predicted that by 2050, antimicrobial resistance could lead to as many deaths as cancer causes today and could account for between 10 million and 50 million deaths per year.

Lack of proper biosecurity

Mc Carlie says the resistance to antibiotics is spreading rapidly due to a lack of proper biosecurity measures in the food and agricultural industry as well as in the hospital environment, even if the COVID-19 pandemic has gone a long way towards increasing the awareness of hospital staff to the importance of good biosecurity. Millions of rands are lost every year due to multidrug-resistant infections in the dairy and poultry industries of South Africa, and superbugs are present in almost every major hospital in the country.

“Currently, the best viable protection we have against bacteria is biosecurity and disinfectants. Biosecurity relies heavily on the use of disinfectants to control bacterial growth. This makes it only more troubling that disinfectant resistance is emerging at an alarming rate.”

She believes it is important to understand the mechanisms of resistance in order to combat resistance to disinfectants. “Once the mechanisms are identified, possible solutions can be investigated.”

The research group is currently monitoring disinfectant resistance, looking at which microorganisms are resistant to which disinfectants. They take environmental samples and test the levels of disinfectant resistance to observe the development and spread thereof.

Once they have an understanding of the development of disinfectant resistance, the Veterinary Biotechnology group will be able to make recommendations to hospitals and the agricultural industry on how to prevent the development of these resistant microorganisms.

“As we learn more about these highly resistant isolates, it will direct day-to-day treatment of multidrug-resistant infections and hopefully aid in the fight against antibiotic and disinfectant resistance,” says Mc Carlie.

The dangers of over-prescribing

“Resistance to antimicrobials such as antibiotics and disinfectants is a natural occurrence. We did not invent antibiotics, we discovered them, and so bacterial resistance has been around for as long as antibiotics have – as a survival strategy.”

“However, the widespread use of antimicrobials creates selective pressure for those microorganisms that are resistant to the antimicrobial being used. Over-prescribing and improper use of antibiotics has led to widespread antibiotic resistance. We expect the same trend to be seen with disinfectant resistance in the near future,” says Mc Carlie.

She urges the public to take note that disease-causing microorganisms can become resistant to antibiotics and disinfectants if they are not used correctly. A course of antibiotics should always be taken at the correct time and until the last dose. In the same way, disinfectants should be used at the recommended level and not diluted below that level.

These resistant organisms are causing major issues in the agricultural and medical industries, but this effect has not been seen in households yet. As long as disinfectants are used correctly, most will be able to kill the novel coronavirus.

There is, however, a need to establish tests on the efficacy of the massive number of ‘hand sanitisers’ that are now suddenly available.

According to Prof Bragg, existing disinfectants and hand sanitisers have been specifically tested against SARS-CoV-2 and have been found to be effective. He says the undergraduate students in the department will be evaluating a wide range of different hand sanitisers as part of their practical training.

Mc Carlie adds that the excessive use of poor-quality disinfectants as hand sanitisers can result in bacteria developing resistance to these disinfectants. “It is therefore very important that reliable high-quality disinfectants are used as hand sanitisers during this COVID-19 crisis, otherwise we will be replacing one crisis with a potentially even bigger crisis.”

Mc Carlie believes there is a need to start looking at alternatives to control bacterial growth. “Disinfectants are currently the only viable option, and if these microorganisms become resistant to disinfectants as well, we will have nowhere else to turn,” she says.

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept